3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
18
Neoplasms
18
Breast Neoplasms
16
Colorectal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
7
Urinary Bladder Neoplasms
6
Hematopoietic and Lymphatic System Neoplasm
6
Hematologic Neoplasms
6
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Mouth Neoplasms
3
Leukemia, Myeloid, Acute
3
Hematopoietic and Lymphoid System Neoplasm
3
Fallopian Tube Neoplasms
3
Carcinoma, Renal Cell
3
Sarcoma
2
Radiodermatitis
2
Peritoneal Neoplasms
2
Pathologic Complete Response
2
Motor Activity
2
Melanoma
2
Malignant Solid Neoplasm
2
Hemangiosarcoma
2
Head and Neck Neoplasms
2
Interventions
Blood Specimen Collection
5
Liquid Biopsy
2
Folfox protocol
2
Carboplatin
2
pertuzumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Sevoflurane
1
Radiotherapy, Adjuvant
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Mastectomy, Segmental
1
Gemcitabine
1
Fluorouracil
1
Epirubicin
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Colonography, Computed Tomographic
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplastic Cells, Circulating
×
Standard of Care
×
Clear all
NCT06391892
2024-04-30
LIQUIPANC
Elisabethinen Hospital
Phase 3
Recruiting
100 enrolled